Filtered By:
Condition: Diabetes
Nutrition: Sodium

This page shows you your search results in order of relevance. This is page number 9.

Order by Relevance | Date

Total 371 results found since Jan 2013.

Differential Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular and Renal Outcomes According to Renal Function: A Dose-Response Meta-Analysis Involving 10 Randomized Clinical Trials and 71,553 Individuals
CONCLUSION: The protective effects of SGLT2i for reducing most adverse cardiovascular and renal outcomes persisted in patients with variable degrees of renal impairment. The observed benefits such as preventing CV death, HF worsening, or stroke may be greater for patients with more severe CKD. Considering the cardiovascular and renal benefits associated with SGLT2i treatment, patients with CKD should be treated aggressively to improve outcomes.PROSPERO REGISTRATION NUMBER: CRD42021273500.PMID:37474112 | DOI:10.1093/ejendo/lvad078
Source: European Journal of Endocrinology - July 20, 2023 Category: Endocrinology Authors: Donna Shu-Han Lin An-Li Yu Hao-Yun Lo Cheng-Wei Lien Jen-Kuang Lee Fu-Tien Chiang Yu-Kang Tu Source Type: research

Sodium-Glucose Cotransporter-2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta-Analysis of Randomized Trials and Systematic Review
Conclusions SGLT2 inhibitors significantly reduced atherosclerotic MACEs in subjects having both chronic kidney disease and type 2 diabetes without established ASCVD.PMID:37581396 | DOI:10.1161/JAHA.123.030578
Source: Atherosclerosis - August 15, 2023 Category: Cardiology Authors: Hammad Rahman Safi U Khan Ahmad N Lone Priyanka Ghosh Mahathi Kunduru Saurabh Sharma Sudhakar Sattur Edo Kaluski Source Type: research

Dapagliflozin Compared to DPP ‐4 inhibitors is Associated with Lower Risk of Cardiovascular Events and All‐cause Mortality in Type 2 Diabetes Patients (CVD‐REAL Nordic): a multinational observational study
ConclusionsDapagliflozin was associated with lower risks of cardiovascular events and all‐cause mortality compared to DPP‐4i in a in a real‐world clinical setting and broad T2D population.
Source: Diabetes, Obesity and Metabolism - August 1, 2017 Category: Endocrinology Authors: F Persson, T Nystr öm, M E Jørgensen, B Carstensen, H L Gulseth, M Thuresson, P Fenici, D Nathanson, J W Eriksson, A Norhammar, J Bodegard, K I Birkeland Tags: ORIGINAL ARTICLE Source Type: research

The effect of SGLT2 inhibitors on cardiovascular events and renal function.
Abstract Introduction Sodium-glucose co-transporters-2inhibitors have emerged as a very promising antidiabetic drug class, with data from the two available cardiovascular trials of this class suggesting remarkable benefits in terms of cardiovascular events, total mortality and renal outcomes. Areas covered Data point toward clinically meaningful benefits from SGLT-2inhibition on a variety of cardiovascular risk factors. Empagliflozin, and to a lesser extent canagliflozin, resulted in significant reductions of an abundance of cardiovascular mortality and morbidity endpoints. SGLT-2inhibitors were also found to redu...
Source: Pharmacological Reviews - August 22, 2017 Category: Drugs & Pharmacology Authors: Imprialos KP, Stavropoulos K, Doumas M, Karagiannis A, Athyros VG Tags: Expert Rev Clin Pharmacol Source Type: research

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
CONCLUSIONS : Patients with type 2 diabetes mellitus and prior cardiovascular events had higher rates of cardiovascular outcomes compared with the primary prevention patients. Canagliflozin reduced cardiovascular and renal outcomes with no statistical evidence of heterogeneity of the treatment effect across the primary and secondary prevention groups. Additional studies will provide further insights into the effects of canagliflozin in these patient populations. CLINICAL TRIAL REGISTRATION : URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01032629 and NCT01989754. PMID: 29133604 [PubMed - as supplied by publisher]
Source: Circulation - November 13, 2017 Category: Cardiology Authors: Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR, CANVAS Program Collaborative Group Tags: Circulation Source Type: research

The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE) –TIMI 58 Trial
Conclusion The DECLARE–TIMI 58 trial is testing the hypotheses that dapagliflozin is safe (does not increase) and may reduce the occurrence of major CV events. DECLARE–TIMI 58 is the largest study to address this question with an SGLT-2 inhibitor in patients with T2DM and with established CV disease and without CV disease but with multiple risk factors.
Source: American Heart Journal - May 8, 2018 Category: Cardiology Source Type: research

Combination of SGLT-2 inhibitors and GLP-1 receptor agonists: potential benefits in surrogate and hard endpoints.
CONCLUSION: The combination of metformin with SGLT2i, GLP-1 RA, and a potent statin, in high CVD risk patients with DM, is expected to substantially reduce CVD mortality and morbidity, improving the quality of life of patients with DM at the same time. Prospective studies are needed to confirm this finding. PMID: 29865997 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - June 3, 2018 Category: Drugs & Pharmacology Authors: Doumas M, Imprialos Κ, Stavropoulos K, Reklou A, Sachinidis A, Athyros VG Tags: Curr Pharm Des Source Type: research

Cardiovascular Protection with Anti-hyperglycemic Agents
AbstractDiabetes mellitus is a major risk factor for cardiovascular (CV) disease. Conversely, CV disease is responsible for a majority of the deaths in patients with diabetes. Many drug trials have concentrated on blood glucose (hemoglobin A1c) reduction. This strategy, while reducing microvascular outcomes like nephropathy and neuropathy, has little or no effect on reducing macrovascular events like heart attack, stroke, and heart failure. It has been postulated that hypoglycemia may counterbalance some of the beneficial effects of anti-hyperglycemic agents, but this is not proven. Further, trial evidence for thiazolidine...
Source: American Journal of Cardiovascular Drugs - February 15, 2019 Category: Cardiology Source Type: research

Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) Reduce Hospitalization for Heart Failure Only and Have No Effect on Atherosclerotic Cardiovascular Events: A Meta-Analysis
ConclusionThe predominant impact of SGLT-2i is on “hHF or CV mortality” composite driven predominantly by reduction in hHF and not atherosclerotic CV disease.
Source: Diabetes Therapy - March 13, 2019 Category: Endocrinology Source Type: research

Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation
In conclusion, the present study identified canagliflozin as a potent inhibitor of human EC proliferation. The anti-proliferative action of canagliflozin is observed in ECs isolated from both the venous and arterial circulation, and is partly due to the blockade of cyclin A expression. In addition, this study found that canagliflozin inhibits tube formation in cultured ECs and mouse aortic rings. Notably, these actions are specific for canagliflozin and not seen with other SGLT2 inhibitors. The ability of canagliflozin to exert these pleiotropic effects on EC function may contribute to both the adverse and salutary actions...
Source: Frontiers in Pharmacology - April 15, 2019 Category: Drugs & Pharmacology Source Type: research

Cardiometabolic disease costs associated with suboptimal diet in the United States: A cost analysis based on a microsimulation model
ConclusionsSuboptimal diet of 10 dietary factors accounts for 18.2% of all ischemic heart disease, stroke, and type 2 diabetes costs in the US, highlighting that timely implementation of diet policies could address these health and economic burdens.
Source: PLoS Medicine - December 16, 2019 Category: Internal Medicine Authors: Thiago Veiga Jardim Source Type: research

24-h urinary sodium excretion and the risk of adverse outcomes.
Conclusion: High sodium intake is associated with an increased incidence of CVD and DM. PMID: 32602794 [PubMed - as supplied by publisher]
Source: Annals of Medicine - July 2, 2020 Category: Internal Medicine Tags: Ann Med Source Type: research

Comparison of glucagons like peptide-1 receptor agonists and dipeptidyl peptide-4 inhibitors regarding cardiovascular safety and mortality in type 2 diabetes mellitus: A network meta-analysis.
CONCLUSION: These data indicate that SGLT-2is is more beneficial to MACE and all-cause mortality in T2DM patients than DPP-4is. PMID: 32888896 [PubMed - as supplied by publisher]
Source: Primary Care - August 31, 2020 Category: Primary Care Authors: Hu J, Chen L Tags: Prim Care Diabetes Source Type: research

Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus.
Conclusion: SGLT2 inhibitors can be a good second-line drug to reduce the incidence of cardiovascular diseases compared with DPP-4 inhibitors or sulfonylureas in people with type 2 diabetes mellitus. PMID: 33120439 [PubMed - as supplied by publisher]
Source: Diabetes and Metabolism Journal - October 31, 2020 Category: Endocrinology Tags: Diabetes Metab J Source Type: research